The effect of D2E7, a new human anti-TNFα monoclonal antibody, on the oxidative burst of PMN in patients with RA.

被引：0
|
作者：
den Broeder, AA
Wanten, GJA
van Riel, PLCM
Kroot, EJ
Naber, THJ
Barrera, P
机构：
[1] Univ Nijmegen Hosp, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen Hosp, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] Generation of fully human anti-TNF antibody D2E7
    Salfield, J
    Kaymakçalan, J
    Tracey, D
    Roberts, A
    Kamen, R
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [2] Improvement in health utility among rheumatoid arthritis (RA) patients treated with adalimumab (D2E7),a fully human anti-TNF monoclonal antibody
    van de Putte, L
    Boggs, R
    Sengupta, N
    Dietz, B
    Bergemann, R
    Rosery, H
    Kupper, H
    VALUE IN HEALTH, 2002, 5 (06) : 461 - 461
  • [3] Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7
    Kempeni, J
    ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 : 70 - 72
  • [4] Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.
    van de Putte, BA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HH
    Compagnone, D
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S400 - S400
  • [5] A dose escalation study designed to demonstrate the safety, tolerability and efficacy of the fully human anti-TNF antibody, D2E7, given in combination with methotrexate (MTX) in patients with active RA.
    Weisman, M
    Keystone, E
    Paulus, H
    Weinblatt, M
    Furst, D
    Moreland, L
    Velagapudi, R
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S391 - S391
  • [6] The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX).
    Keystone, E
    Weinblatt, M
    Furst, D
    Weisman, M
    Moreland, L
    Birbara, C
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S213 - S213
  • [7] One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Dressler, R
    Compagnone, D
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S269 - S269
  • [8] Prevention of polyarthritis in human TNF transgenic mice by D2E7:: A fully human anti-human TNF monoclonal antibody.
    Kaymakçalan, Z
    Haralambous, S
    Tracey, D
    Kamen, R
    Salfeld, J
    Kollias, G
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S97 - S97
  • [9] Treatment with adatimumab (D2E7), a fully human anti-TNF monoclonal antibody improves physical function, vitality, and mental health while reducing bodily pain in patients with active rheumatoid arthritis (RA).
    Revicki, D
    van de Putte, LBA
    Atkins, C
    Malaise, M
    Dietz, B
    Sengupta, N
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S537 - S537
  • [10] Pharmacokinetics of the fully human anti-TNF-α monoclonal antibody adalimumab (D2E7) in the non-human primate.
    Bankmann, Y
    Buehler, V
    Kaymakçalan, Z
    Lassmann, A
    Salfeld, J
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S72 - S72
12345